Fibroblast growth factor (FGF) signaling can bypass the requirement for estrogen receptor (ER) activation in the growth of ER-positive (ER þ ) breast cancer cells. Fibroblast growth factor-1 stimulation leads to phosphorylation of the adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT-1) on C-terminal tyrosine residues, whereas it is constitutively bound through its N-terminal phosphotyrosine-binding domain (PTB) to FGF receptors (FGFRs). By expressing the PTB domain of SNT-1 (SNT-1 PTB) in an inducible manner in an ER þ breast carcinoma line, ML20, we asked whether we could uncouple FGFR activation from its downstream signaling components and abrogate FGF-1-induced antiestrogen-resistant growth. Induction of SNT-1 PTB resulted in a significant decrease of FGF-1-dependent tyrosine phosphorylation of endogenous SNT-1, strong inhibition of complex formation between SNT-1, Gab-1 and Sos-1, and reduced activation of Ras, mitogen-activated protein kinase (MAP kinase), and Akt. SNT-1 PTB also inhibited the phosphorylation of p70S6K on Thr421/Ser424 and Ser411, which may result from the abrogation of MAP kinase activity. Moreover, we also observed a decreased phosphorylation of the MAP kinase-independent site Thr389. This may reflect both inhibition of PI-3 kinase pathways and mammalian target of rapamycin (mTOR)-dependent signaling, as the phosphorylation of Thr389 site was sensitive to treatment with the PI3-K and mTOR inhibitors, LY294002 and rapamycin, respectively. Collectively these results suggest that SNT-1 plays a pivotal role in FGF-dependent activation of the Ras-MAP kinase, PI-3 kinase, and mTOR pathways in these cells. Fibroblast growth factor-1 dependent colony formation of ML20 cells in media containing the pure antiestrogen ICI 182,780 was also markedly inhibited upon induction of SNT-1 PTB, suggesting that blockade of FGFR-SNT-1 interactions might abrogate FGF-mediated antiestrogen resistance in breast cancers.
Fibroblast growth factor (FGF) signaling can bypass the requirement for estrogen receptor (ER) activation in the growth of ER-positive (ER þ ) breast cancer cells. Fibroblast growth factor-1 stimulation leads to phosphorylation of the adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT-1) on C-terminal tyrosine residues, whereas it is constitutively bound through its N-terminal phosphotyrosine-binding domain (PTB) to FGF receptors (FGFRs) . By expressing the PTB domain of SNT-1 (SNT-1 PTB) in an inducible manner in an ER þ breast carcinoma line, ML20, we asked whether we could uncouple FGFR activation from its downstream signaling components and abrogate FGF-1-induced antiestrogen-resistant growth. Induction of SNT-1 PTB resulted in a significant decrease of FGF-1-dependent tyrosine phosphorylation of endogenous SNT-1, strong inhibition of complex formation between SNT-1, Gab-1 and Sos-1, and reduced activation of Ras, mitogen-activated protein kinase (MAP kinase), and Akt. SNT-1 PTB also inhibited the phosphorylation of p70S6K on Thr421/Ser424 and Ser411, which may result from the abrogation of MAP kinase activity. Moreover, we also observed a decreased phosphorylation of the MAP kinase-independent site Thr389. This may reflect both inhibition of PI-3 kinase pathways and mammalian target of rapamycin (mTOR)-dependent signaling, as the phosphorylation of Thr389 site was sensitive to treatment with the PI3-K and mTOR inhibitors, LY294002 and rapamycin, respectively. Collectively these results suggest that SNT-1 plays a pivotal role in FGF-dependent activation of the Ras-MAP kinase, PI-3 kinase, and mTOR pathways in these cells. Fibroblast growth factor-1 dependent colony formation of ML20 cells in media containing the pure antiestrogen ICI 182,780 was also markedly inhibited upon induction of SNT-1 PTB, suggesting that blockade of FGFR-SNT-1 interactions might abrogate FGF-mediated antiestrogen resistance in breast cancers.
Introduction
Various molecular mechanisms are responsible for tumor cells acquiring the ability to grow in the presence of tamoxifen, an antiestrogen effectively used as a therapy for women with estrogen receptor-positive (ER þ ) breast cancer. One such mechanism is the ability of growth factor signaling to confer estrogen independent and antiestrogen-resistant phenotypes to ER þ breast cancer cell lines. Studies from our laboratory have demonstrated that FGF-1-transfected ER þ MCF-7 breast carcinoma lines were capable of forming large, progressively growing tumors in ovariectomized or tamoxifen-treated nude mice suggesting a possible role for FGF signaling in estrogen-independent growth of breast tumors. Moreover, fibroblast growth factor (FGF)-1-transfected MCF-7 cells disseminate and form micrometastases in lymph nodes, lungs, and other organs (McLeskey et al., , 1996 Zhang et al., 1997) . In addition to being resistant to tamoxifen, the FGF-1-transfected cell lines are also cross-resistant to the pure antiestrogen ICI 182,780 (Fulvestrant, Faslodex s ) and aromatase inhibitors (McLeskey et al., 1998) . Since ICI 182,780 leads to rapid degradation of ERa, growth of these cells in the presence of this antiestrogen suggests that FGF signaling may represent a general mechanism allowing ER þ breast cancer cells to bypass ER activation as a requirement for growth.
Upon activation, FGF receptors undergo rapid autophosphorylation. Unlike other growth factor receptors, FGFR-dependent activation of the Ras/mitogenactivated protein kinase (MAPK) pathway does not occur through direct binding of the Grb2 protein to the ligand-activated receptor as this receptor lacks the consensus pYXN-binding site for the SH2 domain of Grb2. Instead, this signaling pathway involves a docking protein SNT-1 (Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target) which connects FGFR to downstream components of the FGF-activated pathways.
Human SNT-1, and its murine homologue FRS2a (FGF receptor substrate 2a), appear to be critical links in FGF signaling (Rabin et al., 1993; Kouhara et al., 1997; Hadari et al., 2001) . The N-terminal 140 amino acids of this protein contain a myristylation signal that targets the protein to the membrane, followed by a phosphotyrosine-binding (PTB) domain which binds constitutively to juxtamembrane regions of receptors (Xu et al., 1998) . The SNT-1 C-terminal region contains multiple tyrosine residues which are phosphorylated in response to FGF addition (Xu and Goldfarb, 2001 ). Phosphorylation of tyrosine residues within the C-terminal portion of SNT-1 allows the protein to function as a scaffold that assembles other proteins that are involved in transmitting the growth signal (Ong et al., 1996) . Fibroblast growth factor stimulation results in phosphorylation of tyrosines 196, 306, 349, and 392 of SNT-1/FRS2, which are binding sites for the SH2 domain of Grb2, as well as tyrosines 436 and 471, which bind the SH2 domains of Shp2. The SNT-1 bound Grb2 then interacts via its amino-terminal SH3 domain with the nucleotide exchange factor Sos1 (Wang et al., 1996; Kouhara et al., 1997; Ong et al., 2001) . This interaction leads to activation of the Ras/MAPK pathway. The SNT-1-mediated activation of Shp2 is essential for sustained activation of MAP kinase and for potentiation of FGF-induced PC12 cell differentiation (Hadari et al., 1998; Ong et al., 2001) .
Grb2 bound through its SH2 domain to tyrosinephosphorylated SNT-1/FRS2 also interacts primarily via its C-terminal SH3 domain with the proline-rich region in Gab1. In Swiss 3T3 fibroblasts, assembly of FRS2:Grb2:Gab1 complex induced by FGF stimulation results in activation of PI3-kinase and downstream effector proteins such as Akt, whose cellular localization and activity are regulated by products of PI3-kinase (Ong et al., 2001) . Thus, the multiprotein docking complex assembled upon SNT-1 activation can not only activate the Ras/MAPK signaling pathway but also the PI3-kinase pathway (Ong et al., 2001) .
Because much of the published literature suggests a pivotal role for SNT-1 in FGF signaling, we investigated whether we could selectively block FGF-induced responses in ER þ breast cancer cells by overexpression of its PTB domain. To evaluate whether SNT-1 functions as a critical link for FGF signaling in breast cancer cells and whether blocking FGF signaling at the level of SNT-1 could inhibit antiestrogen resistant growth, we assessed the potential dominant negative effect of SNT-1 PTB domain overexpression. We overexpressed the N-terminal PTB plus myristylation domains of SNT-1 (SNT-1 PTB) in a doxycycline (Dox)-inducible manner in a derivative of the MCF-7 cell line and tested its effects on activation of signaling pathways induced by FGF-1 treatment in estrogen-depleted conditions. We demonstrate a strong dominant negative effect upon induction of SNT-1 PTB expression on the activation of various components in the Ras-MAPK, PI3-kinase, and mammalian target of rapamycin (mTOR) signaling pathways. We also showed an inhibitory effect of SNT-1 PTB overexpression on antiestrogen-resistant FGF-1-dependent growth.
Results
Doxycycline-inducible expression of SNT-1 PTB Two proteins, SNT-1 and SNT-2 (murine homologueFRS2b), have been identified as FGFR adapter molecules. SNT-2/FRS2b shows 49% amino-acid sequence identity to SNT-1 and has a similar domain structure suggesting that it could possibly compensate for SNT-1 function in breast cancer cells (Xu et al., 1998) . Therefore, prior to investigating the role of SNT-1 PTB in ML20 breast cancer cells, we examined the expression of both SNT-1 and SNT-2 genes in these cells by RT-PCR. We attempted to amplify cDNAs of both proteins using total RNA isolated from placenta and from ML20 cells. Although SNT-1 was readily detectable in both sources, SNT-2 was undetectable in ML20 cells under conditions where it could be easily amplified in placental RNA (data not shown). As ML20 cells do not express detectable levels of SNT-2, we have chosen this cell line to study the potential dominant negative effect of the SNT-1 PTB domain in FGF-mediated antiestrogen resistance of ER þ breast cancer cells.
To avoid outgrowth of cells that bypass SNT-1 by utilizing compensatory mechanisms during expansion of SNT-1 PTB expressing stably transfected populations, we employed a regulatable system that allows expression of SNT-1 PTB only in the presence of Dox. The cDNA of the c-myc-tagged SNT-1 PTB fusion protein was cloned into pTREins to express it under Dox regulation (Qu et al., 2004) . C9 cells, an ML20 subline that stably expresses rtTA2S-M2, was stably transfected with this vector. Polyclonal populations and several clonally isolated lines were derived. First, we demonstrated by immunofluorescence staining with an anti-c-myc antibody that SNT-1 PTB was uniformly induced with Dox treatment (200 ng/ml) in Clones 29 and 13 with almost undetectable expression in uninduced cells (Figure 1a) . Polyclonal populations showed a mosaic expression pattern. High level of SNT-1 PTB expression in clones 29 and 13 with undetectable basal expression was confirmed by Western blotting with c-myc antibodies (Figure 1b) . Doxycycline-induced SNT-1 PTB expression abrogates FGF-1-induced phosphorylation of endogenous SNT-1 and its interaction with Gab1 and Sos1 To determine whether Dox-inducible SNT-1 PTB can function as a dominant negative signaling molecule, we tested the levels of wild-type SNT-1 tyrosine phosphorylation in the p13
Suc1 captured fraction of Clone 29 cellular lysates before and after Dox induction. Fibroblast growth factor-1 supplementation of the media caused tyrosine phosphorylation of endogenous SNT-1 in control cells transfected with vector pTRE-Ins alone as evidenced by the increased intensity of two bands following Western blotting with antiphosphotyrosine antibody. Two bands were observed with this antibody because SNT-1/FRS2 undergoes an electrophoretic mobility shift that is caused by its phosphorylation on serine/threonine residues in response to FGF stimulation (Kouhara et al., 1997; Lax et al., 2002) . Induction of SNT-1 PTB with Dox blocked the FGF-1-induced tyrosine phosphorylation of endogenous SNT-1 in Clone 29 cells (Figure 2a) . To confirm the specificity of the SNT-1 PTB inhibitory effect on SNT-1-mediated aspects of the FGF signaling pathway, we examined its influence on FGF-dependent activation of another mediator of FGF signaling, Shc A, a docking protein involved in multiple signaling pathways. This protein becomes phosphorylated upon FGF-1 treatment of estrogen-depleted ML20 cells (unpublished data). Others have shown the FGF-dependent phosphorylation of Shc in other cell lines (Klint et al., 1995 (Klint et al., , 1999 . It has been suggested that the Tyr730 of FGFR may serve as a potential bidning site for Shc although a physical interaction of Shc with the receptor has not been confirmed (Dunican et al., 2001) . Even though Shc may not bind FGFR directly, it still may activate pathways in response to FGF treatment that are alternative to those mediated by the interaction of SNT-1/FRS2 with FGFRs. The levels of FGF-1-mediated phosphorylation of Shc 52 isoform upon Dox-mediated induction of SNT-1 PTB remained unchanged (Figure 2b ), indicating that FGFRs remain activated and expressed at similar levels in the presence of the overexpressed SNT-1 PTB domain. Control treatment of the same cells with heregolin b1 (HRG-b1) also resulted in increased Shc The SNT-1 PTB was induced with Dox (200 ng/ml) for 24 h. The cells were then stripped of estrogens with three changes of 5% CCS-PRF-IMEM medium over 8 h and incubated overnight in serum-free PRF-IMEM medium. During this process, Dox remained present where indicated. In all, 5 mg of total cellular lysates were electrophoresed on 8-16% gradient polyacrylamide gels followed by immunoblotting with a monoclonal anti-myc antibody.
Figure 2 Dox-inducible expression of the phosphotyrosine-binding domain (PTB) of SNT-1 (SNT-1 PTB) in MCF-7 cells blocks fibroblast growth factor (FGF)-1 induced tyrosine phosphorylation of the endogenous SNT-1 protein and inhibits its association with Gab1 and Sos1, but does not inhibit the FGF-1-mediated activation of Shc isoform p52. C9 cells stably transfected with pTREins/ PTB or empty vector were induced by doxycycline (Dox) and stripped of estrogens as described in Figure 1b . Cell were then treated with FGF-1 (20 ng/ml) and heparin (50 mg/ml) or with heregulin b1 (HRG-b1) (25 ng/ml) in serum-free PRF-IMEM for 30 min. (a). Tyrosine phosphorylation of endogenous SNT-1 and complex formation with Gab1 and Sos1 are shown in p13 Suc1 agarose captured fractions from 2 mg of total cell lysates, followed by electrophoresis and immunoblotting with anti-phosphotyrosine, anti-FRS2, Gab1 and Sos1 antibodies. In all, 5 mg of cellular lysates used for precipitation with p13
Suc1 agarose were electrophoresed on polyacrylamide gel followed by immunoblotting with a monoclonal anti-myc antibody for the SNT-1 PTB expression control. (b) Total cellular protein (80 mg) was loaded in each well for immunoblotting with phospho-Shc and Shc antibodies.
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To further explore the dominant negative effect of SNT-1 PTB expression on FGF signaling, we determined the ability of endogenous SNT-1 to form a complex with Gab1 and Sos1 proteins upon FGF-1 treatment in cells where expression of the PTB domain is induced with Dox treatment. Endogenous SNT-1 was precipitated by p13
Suc1 agarose from estrogen-depleted and FGF-1-stimulated cellular lysates in the presence and in the absence of Dox. The presence of Gab1 and Sos1 proteins in the p13
Suc1 agarose captures was determined by Western blotting. As demonstrated in Figure 2 , upon Dox induction of SNT-1 PTB, the involvement of Gab1 and Sos1 in the multiprotein complex with SNT-1 in FGF-dependent conditions was significantly decreased in Clone 29 cells but not in control cells. Thus, abrogation of the recruitment of multiple proteins to the C-terminus of wild-type SNT-1 confirmed the dominant negative action of the SNT-1 PTB domain in MCF-7 cells.
Dox-induced SNT-1 PTB expression prevents activation of Ras and MAP kinase by FGF-1
Formation of the complex of SNT-1 with Grb2 and Sos1 proteins is considered an initial step in the activation of the Ras/Raf/MAPK signaling pathway (Kouhara et al., 1997) . Since the FGF-1-induced association of Sos1 with endogenous SNT-1 was inhibited by expression of SNT-1 PTB, we expected that activation of Ras by FGF-1 would also be inhibited. Indeed, in the lysates of cells stably transfected with pTREins/PTB plasmid (Clone 13 and Clone 29), we observed a significant reduction of Ras binding to the Ras-binding domain of Raf-1 upon induction of SNT-1 PTB by Dox and treatment with FGF-1 (Figure 3) . In control cells, Ras activation by FGF-1 remained uninfluenced by Dox treatment. The specificity of Ras inhibition for FGF-dependent conditions was confirmed by the absence of a Ras inhibitory effect by SNT-1 PTB expression upon HRG-b1 treatment (Figure 3 ), since SNT-1 has not been implicated in HRG-b-1 signaling. Next, we determined the level of MAPK phosphorylation by Western blotting of total lysates from cells stimulated with FGF-1, HRG-b1, or 5% fetal bovine serum (FBS) upon induction of SNT-1 PTB expression with Dox ( Figure 4 ). We found that Dox treatment at 200 ng/ml did not cause significant changes in the levels of MAPK activation in untransfected cells or in the cells transfected with vector alone after any of the treatments (Figure 4 ). On the other hand, when Dox was added to Clone 29 and Clone 13 cells, FGF-induced phosphorylation of MAPK decreased to basal levels ( Figure 4 ). Exposure to HRG-b1 caused much greater level of MAPK phosphorylation than FGF-1 treatment and these levels remained unchanged upon induction of SNT-1 PTB with Dox. Since MAPK activation represents a major step in FGF-dependent proliferation of breast cancer cells, its significant inhibition in Clone 29 and Clone 13 cells in FGF-1-dependent but not HRG-b1-dependent conditions confirms specificity of the dominant negative effect of SNT-1 PTB in MCF-7 cells. Thus, we observed a strong inhibition of the main components of MAP kinase pathway upon FGF-1 induction of cells expressing the SNT-1 PTB domain.
SNT-1 PTB domain inhibits the activation of components of the PI3-kinase pathway
In response to FGF-1 stimulation, activation of the PI3-kinase/Akt signaling pathway is mediated by binding of the SH2 domain of Grb2 to tyrosine-phosphorylated SNT-1 and its SH3 domain to a proline-rich region of Gab1 (Ong et al., 2001 ). As we demonstrated a significant inhibition of the involvement of Gab1 in the SNT-1-associated multiprotein complex by SNT-1 PTB expression in MCF-7 cells, it would be reasonable to expect a dominant negative effect of this molecule in the PI3-kinase pathway. Activation of Akt (PKB), a Figure 1b . Cells were then treated with fibroblast growth factor (FGF)-1 (20 ng/ml) and heparin (50 mg/ml) or heregulin b1 (HRG-b1) (25 ng/ml) for 5 min. Cells were lysed and 500 mg of cellular lysate was incubated with Raf-1 RBD agarose (10 ml) at 41C for 30 min. The agarose pull-downs were washed three times with lysis buffer, boiled with 2 Â Laemmli sample buffer and electrophoresed on SDS-PAGE gels, followed by immunoblotting with anti-Ras antibodies. The membranes were stripped and reprobed with anti-glutathione-s-transferase (GST) antibodies. For control of the expression of SNT-1 PTB, 5 mg of total cellular lysates were electrophoresed on polyacrylamide gel followed by immunoblotting with a monoclonal anti-myc antibody.
SNT-1 PTB domain blocks FGF-mediated antiestrogen resistance M Manuvakhova et al downstream effector of PI3-kinase, is accompanied by its phosphorylation at Thr308 and Ser473, which is prevented by the PI3-kinase inhibitors (Alessi et al., 1996) . In C9 cells transfected with pTREins/PTB (Clone 29 and Clone 13) or empty pTREins vector, maximum phosphorylation of Ser473 site of Akt was observed after 5 min of incubation with FGF-1 in estrogendepleted conditions with a subsequent substantial decrease at 15 min of incubation ( Figure 5 ). Upon Dox-mediated induction of SNT-1 PTB, the phosphorylation of Akt was significantly inhibited at all time intervals, whereas in C9 cells transfected with the empty vector it remained unchanged ( Figure 5 ). Control treatment of the same cells with HRG-b1 resulted in dramatic increases of Akt phosphorylation levels, which were insensitive to the PTB domain expression, as was expected ( Figure 5 ). Another important mediator of the PI3-kinase pathway is the mitogen-stimulated serine/threonine kinase p70S6K, which modulates the translation of an mRNA subset that encodes ribosomal proteins and translation elongation factors (Cheatham et al., 1995; Romanelli et al., 1999 Romanelli et al., , 2002 Gonzalez-Garcia et al., 2002) . It plays a role in cell survival signaling by inactivating the proapoptotic molecule BAD (Harada et al., 2001) , as well as in cell growth. Activity of p70S6K is regulated by phosphorylation of eight different residues distributed throughout the protein (Ferrari et al., 1992; Han et al., 1995; Dennis et al., 1998; Romanelli et al., 2002) . We investigated the effects of SNT-1 PTB overexpression on phosphorylation of sites Thr421/Ser424 and Ser411, located in the pseudosubstrate domain of p70S6K, and on Thr389, which is critical for protein activity and located in the linker site of p70S6K (Dennis et al., 1998) . Results of Western blot analysis showed that phosphorylation of all these sites was induced by FGF-1 as well as HRG-b1 in cells transfected with the control vector pTREins alone and this was not influenced by Dox (Figure 6a and b) . Fibroblast growth factor-induced phosphorylation of the MAPK-dependent sites Thr 421/Ser424 and Ser411 in cells stably expressing Dox-inducible SNT-1 PTB (Clone 13 and Clone 29) was decreased to basal levels upon Dox induction (Figure 6a ). The phosphorylation of Thr389 site, on the other hand, is dependent on PI3-kinase and mTOR activation. We found that unlike the activation of Akt, which reaches the maximum after about 5 min of incubation with FGF-1 and significantly decreases by 30 min, Thr389 of p70S6K remains phosphorylated at the same level for at least 2 h after stimulation by FGF-1 (not shown). Activation of Thr389 site was inhibited by inducible expression of SNT-1 PTB at all time points (Figure 6b and not shown). However, HRG-b1-induced phosphorylation of all three p70S6K sites remained unchanged at the same concentration of Dox, which confirmed the specificity of these effects for the FGF signaling pathway (Figure 6a and b) . Mitogen-induced activation of p70S6K requires multiple inputs including Figure 4 Phosphotyrosine-binding domain (PTB) of SNT-1 (SNT-1 PTB) specifically reduces fibroblast growth factor (FGF)-1 stimulated mitogen-activated protein kinase (MAPK) phosphorylation when overexpressed in a doxycycline Dox regulatable manner. C9 cells stably transfected with pTREins/PTB or an empty vector were induced by Dox and stripped of estrogens as described in Figure 1b . Mitogen-activated protein kinase phosphorylation was induced by a 30 min incubation with FGF-1 (20 ng/ml) and heparin (50 mg/ml), or heregulin b1 (HRG-b1) (25 ng/ml), or 5% fetal borine serum. Total cellular protein (30 mg) was loaded in each well for immunoblotting with phospho-MAPK and MAPK antibodies. Figure 5 Phosphotyrosine-binding domain (PTB) of SNT-1 (SNT-1 PTB) inhibits fibroblast growth factor (FGF)-1 stimulated Akt phosphorylation when overexpressed in a doxycycline (Dox) regulatable manner. C9 cells stably transfected with pTREins/PTB or empty vector were induced by Dox and stripped of estrogens as described in Figure 1b . Akt phosphorylation was induced by incubation with FGF-1 (20 ng/ml) and heparin (50 mg/ml) for designated time intervals or heregulin b1 (HRG-b1) (25 ng/ml) for 30 min. Total cellular protein (80 mg) was electrophoresed on SDS-PAGE gels followed by immunoblotting with phospho-Akt and Akt antibodies. For control of the expression of SNT-1 PTB, 5 mg of total cellular lysates were electrophoresed on polyacrylamide gel followed by immunoblotting with a monoclonal anti-myc antibody.
SNT-1 PTB domain blocks FGF-mediated antiestrogen resistance M Manuvakhova et al PI3-kinase-and mTOR-dependent activation resulting in phosphorylation of Thr389 (Dennis et al., 1998; Romanelli et al., 1999; Gonzalez-Garcia et al., 2002) . Consistent with this idea, we also show that the PI3-kinase inhibitor LY294002, as well as rapamycin, an inhibitor of mTOR, completely blocked the FGF-1-induced phosphorylation of Thr389 in these cells (Figure 6c ). On the other hand, since Thr389 has been shown to be independent of the Erk pathway, the MEK1/2 inhibitor U0126 (Favata et al., 1998) did not influence the FGF-1-dependent phosphorylation of this site (Figure 6c) .
Expression of SNT-1 PTB decreases anchoragedependent and FGF-1-mediated growth of ML20 cells We employed a colony-forming test to study if the Dox-inducible expression of SNT-1 PTB would be able to prevent FGF-1-dependent antiestrogen-resistant growth of these cells. ICI 182,780 significantly repressed Figure 6 Phosphotyrosine-binding domain (PTB) of SNT-1 (SNT-1 PTB) inhibits FGF-1-induced phosphorylation of Thr421/ Ser424, (a) Ser411, and Thr389 (b) sites on p70S6K. Fibroblast growth factor-1 (FGF-1) stimulated phosphorylation of Thr389 site of p70S6K is inhibited by LY294002 and rapamycin. (c) C9 cells stably transfected with pTREins/PTB or empty vector were induced by doxycycline (Dox) and stripped of estrogens as described in Figure 1b . p70S6K phosphorylation was induced by a 30 min incubation with FGF-1 (20 ng/ml) and heparin (50 mg/ml) or heregulin b1 (HRG-b1) (25 ng/ml). Total cellular protein (80 mg) was fractionated on SDS-PAGE gels followed by immunoblotting with antibodies against phospho-Thr 421/Ser 424, phospho-Ser 41, and phosphoThr389, of p70S6K. Cells were stripped of estrogen, pretreated for 30 min with 3 mM of LY294002 or rapamycin (3 nM) and induced by a 30 min incubation with FGF-1 (20 ng/ml) and heparin (50 mg/ml). LY294002 and rapamycin remained in the medium at the time of induction with FGF-1. Total cellular protein (80 mg) was fractionated on SDS-PAGE gels followed by immunoblotting with antibodies against phospho-Thr389 of p70S6K. Figure 7 ). The addition of Dox to the growth medium of cells transfected with the control vector pTREins did not show a significant inhibition of colony formation, whereas the induction of SNT-1 PTB in Clone 29 cells almost completely abrogated colony formation observed when FGF-1 was added to ICI 182,780. It is interesting to note that we also observed a minor but statistically significant decrease of growth in the presence of 5% FBS when expression of the PTB domain was induced.
We did not observe a significant influence of the SNT-1 PTB expression on the anchorage-dependent growth mediated by HRG-b1 or by 17b-estradiol in the presence of ICI 182,780. These results indicate that induction of SNT-1 PTB can abrogate the growth stimulatory effects of FGF in breast cancer cells that permit antiestrogen-resistant growth, and, in addition, affects the growth mediated by serum.
Discussion
Our results demonstrate that SNT-1/FRS2 plays a critical role as a 'docking' molecule for multiple proteins involved in signal transduction from the FGFR to downstream components of the FGF signaling pathway, and that these components are important in antiestrogenresistant growth of ER þ breast cancer cells mediated by FGF-1. The PTB domain of SNT-1 binds constitutively to nonphosphorylated FGF receptors in a region lacking tyrosine or asparagines (Dhalluin et al., 2000; Ong et al., 2000) . Upon FGFR phosphorylation, SNT-1 becomes activated by phosphorylation of its multiple tyrosines. It was of interest to determine if abrogation of the interaction of SNT-1 with FGFR by overexpressed SNT-1 PTB would be sufficient to inhibit FGF-stimulated proliferation of breast cancer cells.
We used a modified Dox-regulatable expression system which permitted isolation of cell populations that would not select for mechanisms that would compensate for the negative effects of overexpressed SNT-1 PTB (Qu et al., 2004) . Using clonal lines we demonstrated that inducible SNT-1 PTB blocks FGF-1-induced tyrosine phosphorylation of endogenous SNT-1 and its association with other components of the multiprotein complex such as Gab1 and Sos1. Subsequently, we found significant diminution of the activation of Ras and MAP kinase. As SNT-1 has not been shown to be involved in erbB2-, erbB3-, or erbB4-mediated signaling pathways, both Ras and MAP kinase remain activated in SNT-1 PTB-expressing cells stimulated by HRG-b1. This result confirms the specificity of SNT-1 effects for the FGF signaling pathway.
As expected from the decrease of Gab1 in the SNT-1 multiprotein complex, we detected a significant inhibition of FGF-1-induced activation of Akt, a downstream PI3-kinase mediator, upon inducible expression of SNT-1 PTB. This is in agreement with published reports showing that overexpression of FRS2a or Gab1 can potentiate FGF-induced Akt phosphorylation (Ong et al., 2001 SNT-1 PTB domain blocks FGF-mediated antiestrogen resistance M Manuvakhova et al was able to rescue FGF-1-induced PI3-kinase and Akt activation when expressed in Gab1 À/À cells and FRS2
À/À cells derived from mouse embryo fibroblasts, which underscores the essential role of Gab1 in FGF stimulation of PI3-kinase/Akt signaling pathways (Lamothe et al., 2004) . The Akt inhibitory effect of SNT-1 PTB was FGF-1-specific as HRG-b1-mediated phosphorylation of the Ser473 site of Akt was not inhibited. To examine if signaling mechanisms lying downstream of MAP kinase and PI3-kinase could also be abrogated by expression of SNT-1 PTB, we studied the levels of phosphorylation of p70S6K. Phosphorylation of the multiple activation sites of this protein results from activation of different signaling pathways (Iijima et al., 2002; Gonzalez-Garcia et al., 2002) . Mitogen stimulation is hypothesized to first lead to increased phosphorylation of sites located within the C-terminal pseudosubstrate domain (Thr421/Ser424 and Ser411) (Han et al., 1995) , which functions together with the amino-terminus to facilitate phosphorylation of Thr389 located in the linker region. The phosphorylation of Thr 421/Ser424 is regulated through the c-Raf/MEK/extracellular signal-regulated kinase (ERK) pathway in an mTOR-independent and wortmannin-independent manner (Price et al., 1991; Iijima et al., 2002) . Phosphorylation of Ser411 is also MAPK dependent although wortmannin has a weak effect on the phosphorylation of this site (Han et al., 1995; Zhang et al., 2001 ). As we observed an inhibitory effect of SNT-1 PTB expression on the components of Ras/MAPK pathway and also simultaneously on the phosphorylation of sites Thr421/ Ser424 and Ser411 of p70S6K, we suggest that inhibition of the phosphorylation of these sites by SNT-1 PTB may result from the strong inhibition of MAP kinase activity.
The linker region of p70S6K is thought to couple its C-terminal and catalytic domains thereby regulating phosphorylation of Thr229 in the catalytic domain which is critical for kinase activation (Dennis et al., 1998) . Thr389 in the linker region is the principal regulatory phosphorylation site acutely regulated by external effectors. Phosphorylation of the Thr389 site is independent of MAP kinase activation and is coordinately controlled by the PI3-kinase-and mTORdependent signals. This was confirmed by our data demonstrating complete abrogation of FGF-1-dependent Thr389 phosphorylation in MCF-7 cells by the PI3-kinase inhibitor, LY294002, as well as rapamycin, an inhibitor of mTOR. In addition to Thr389, phosphorylation of Thr229 is also rapamycin-and wortmanin-sensitive, suggesting a role for both mTOR-and PI3-kinase dependent pathways in its phosphorylation (Han et al., 1995; Dennis et al., 1998; Gonzalez-Garcia et al., 2002) .
Because phosphorylation of p70S6K is sensitive to inhibition by both wortmanin and rapamycin, researchers often place PI3K and mTOR in a linear signaling pathway. The recent discoveries that the PI3K/AKT/ TSC/Rheb pathway lies upstream of mTOR (reviewed in Manning and Cantley (2003) ; Fingar and Blenis (2004) , and the interaction of mTOR with raptor and GbL both highlight the complexity of mTOR regulation (Hara et al., 2002; Kim et al., 2003; Yonezawa et al., 2004) . Thus, a current model suggests that PI3-kinase lies both upstream and parallel to mTOR, with both branches converging on common downstream targets, such as p70S6K (Fingar and Blenis (2004) . Sustained and prolonged (up to 2 h) phosphorylation of the p70S6K Thr389 site by FGF-1 in our experiments may be mediated by PI3-kinase as well as mTOR signaling pathways. Inhibitory effect of SNT-1 PTB on phosphorylation of Thr421/Ser 424, Ser 411, and Thr389 sites of p70S6K in concert with LY294002 and rapamycin-mediated inhibition of this site illustrates the negative effect SNT-1 PTB on multiple FGF-mediated signaling pathways, including MAP kinase, PI3-kinase, and potentially mTOR signaling. This emphasizes the critical role of SNT-1 molecule in mediating an FGF-dependent antiestrogen resistance in ER þ breast cancer cells.
Consistent with the inhibition of FGF-dependent activation of the Ras-MAP kinase and PI3 kinase-Akt pathways, we observed almost complete abrogation of FGF-1-dependent antiestrogen-resistant growth of MCF-7 cells when SNT-1 PTB was induced (Figure 7 ). The colony formation by MCF-7 cells transfected by the vector pTREins alone was essentially unperturbed by the addition of Dox. Although the anchorage-dependent growth mediated by HRG-b1 or by 17b-estradiol in the presence of ICI 182,780 was not inhibited by induction of SNT-1 PTB, we observed a minor but statistically significant inhibition of serum-mediated colony formation. Very recently, a new role for SNT-1/FRS2 in cell cycle progression has been described. Unphosphorylated SNT-1 was shown to interact with the Cks1 protein in NIH 3T3 fibroblasts, which triggers ubiquitination and degradation of p27
Kip1 (Zhang et al., 2004) . The FGFR-dependent phosphorylation of FRS2 causes release of Cks1 from FRS2 thus promoting degradation of p27 Kip1 followed by activation of the cyclin A/E-Cdk complex and leading to G1/S transit. Moreover, Cks1 associates with FRS2 through the latter's PTB and myristylation domains (Zhang et al., 2004) . We have also demonstrated that full-length SNT1, as well as SNT-1 PTB, associates with Cks1 in MCF-7 breast adenocarcinoma cells (unpublished data). The sequestration of Cks1 by overexpressed SNT-1 PTB with subsequent stabilization of p27
Kip1 and inhibition of the G1/S transition may provide an explanation of the inhibitory effect of SNT-1 PTB in various serummediated pathways. Studies examining these possibilities are in progress. Although these findings may explain the inhibitory effect of overexpressed SNT-1 PTB in FBS-dependent conditions in our system, SNT-1-Cks1 interactions may not be important components of these pathways under normal physiological levels of SNT-1 expression. It remains to be determined to what extent the SNT-1-Cks1 interaction might be contributing to the observed decrease in growth in FGF-1-dependent conditions. However, it is likely that it is the uncoupling of important downstream signaling events from FGF receptor activation that is the primary cause of the growth inhibition in FGF-dependent growth conditions.
SNT-1 PTB domain blocks FGF-mediated antiestrogen resistance M Manuvakhova et al
It is also possible that inhibition of colony outgrowth upon SNT-1 PTB expression in Clone 29 cells treated with 5% FBS might be owing to SNT-1 involvement in pathways triggered by serum components. For example, stimulation of ovarian adenocarcinoma cells with G-protein-coupled receptor (GPCR) agonists induces a shift in the migration of FRS2a (Wu et al., 2003) , which has been shown to be mediated by Erk-dependent serine/threonine phosphorylation of FRS2a (Lax et al., 2002) . A significant part of this effect was suggested to be because of the release of epidermal growth factor (EGFR) ligands from membrane-bound precursors through GPCR agonists-induced protease activity (Wu et al., 2003) . Therefore, it is likely that EGFR ligands in serum may in part be responsible for this effect.
Besides its importance in the FGF pathway, SNT-1/ FRS2 plays the role of a receptor docking protein in other receptor tyrosine kinase pathways. It participates in signal transduction from the TrkA receptor induced by nerve growth factor (NGF) (Kouhara et al., 1997; Meakin et al., 1999) and TrkB and TrkC receptors activated by BDNF and NT-3 growth factors (Tsoulfas et al., 1996; Yuen and Mobley 1999) . The PTB domain of SNT-1 also binds to the RET receptor tyrosine kinase that is activated by glial cell line derived factor (GDNF) or multiple endocrine neoplasia (MEN) 2 mutations (Califano et al., 2000; Kurokawa et al., 2001) . Although the published data concerning the involvement of SNT-1 in the EGF signaling pathway are contradictory, the PTB domain has also been identified as part of the vascular endothelial growth factor (VEGF)-dependent pathways, an important mechanism of breast cancer progression (Rabin et al., 1993; Kimpinski and Mearow 2001; Stoletov et al., 2002; Wu et al., 2003) . These data may imply an as yet unknown role of SNT-1 in some additional pathways. It is also possible that endogenous FGFs produced by MCF-7 cells contribute to growth even in the absence of antiestrogens and that SNT-1 PTB expression antagonizes these growth pathways when cells are incubated simply in FBS, possibly explaining its slight inhibitory effects on colony formation in serum-containing conditions. To rule out the possibility that non-specific effects caused by protein overexpression are responsible for inhibition of anchorage-dependent growth, we stably transfected the same cell line with an inducible full-length SNT-1. In this line, we did not observe any inhibition of MAPK phosphorylation or growth factor-induced proliferation, which supports the specificity of the inhibitory effects as being due to SNT-1 PTB expression.
Although expression of four fibroblast growth factor receptors has been detected in human breast tumors or cells lines (Jaakkola et al., 1993; Penault-Llorca et al., 1995; Yoshimura et al., 1998; Koziczak et al., 2004; Moffa et al., 2004) , the role of SNT-1/FRS2 is predominantly defined in FGFR1-induced pathways. Sequence alignment of the potential SNT-1-binding site in the juxtamembrane region of FGFR-1 with the juxtamembrane domains of the FGFR-2, -3, and -4 receptors demonstrates that SNT-1 can potentially bind all four receptors (not shown). Indeed, the direct interaction of SNT-1 with FGFR3 receptor has already been demonstrated (Ehrhard et al., 2000) . It has also been shown that the quantity and quality of SNT-1 phosphorylation is both FGFR isotype and cell typespecific in prostate epithelial cells at different stages of malignancy (Wang, 2002) . It is possible that in breast cancer cells, the efficiency of SNT-1 PTB interaction with different FGF receptor isotypes can be variable, leading to different degrees of abrogation of FGFdependent pathways. This question needs to be addressed in the future. In summary, our results showing the inhibition of major FGF-dependent signaling pathways, as a well as antiestrogen-resistant cell growth by a dominant negative mutant of SNT-1 in breast cancer cells, characterizes SNT-1 as a potential target for novel breast cancer therapies. In future, we plan to examine the ability of SNT-1 PTB to inhibit the FGF-dependent breast tumor growth in xenograft model.
Materials and methods
Chemicals, growth factors, and immunological reagents Anti-Gab1, anti-Sos1, anti-Grb2 (clone 3F2), anti-Shc, antiphospho-Shc (Y317), anti-phosphotyrosine (clone 4G10) antibodies, p13
Suc1 agarose, and the Ras activation kit were obtained from Upstate Biotechnology (Charlottesville, VA, USA). Anti-FRS2a was from Santa Cruz Biotechnology (Santa-Cruz, CA, USA). Anti-c-myc used for immunoblotting was from Oncogene Research Products (San Diego, CA, USA), and anti-c-myc used for immunofluorescence was from Invitrogen (Carlsbad, CA, USA). The PhosphoPlus AKT (Ser473) antibody kit, and the PhosphoPlus Map kinase (Thr202/Tyr204) antibody kit were from Cell Signaling Technology (Beverly, MA, USA) and the PhosphoPlus p70S6 kinase antibody kit (Thr389, Ser411, Thr421/Ser424) was from New England BioLabs (Beverly, MA, USA). GST antibody was purchased from Pharmacia Biotech (Piscataway, NJ, USA). Texas Red dye-conjugated AffiniPure donkey anti-mouse IgG and normal goat serum were from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Protein A Sepharose was from Pharmacia Biotech (Piscataway, NJ, USA). Recombinant human FGF-1 was obtained from Promega (Madison, WI, USA) and HRG-b1 was from R&D Systems (Minneapolis, MN, USA). ICI 182,780 (Faslodex s ) was a gift from AstraZeneca (Waltham, MA, USA) or was obtained from Tocris (Ellisville, MO, USA). 17b-Estradiol and heparin were from Sigma (St Louis, MO, USA) and LY294002 and rapamycin were from Calbiochem (San Diego, CA, USA). U0126 was obtained from Promega (Madison, WI, USA).
Cell lines and cell culture
Breast cancer cell line ML-20 is a clonally derived subline of MCF-7 that is stably transfected with a LacZ expression vector . Cells were maintained in improved modified Eagle's medium (IMEM) (Mediatech, Inc., Herndon, VA, USA), supplemented with 5-10% fetal bovine serum (FBS, Gibco Invitrogen Corporation, Carlsbad, CA, USA). In some experiments, 5% charcoal-stripped calf serum (CCS) in phenol red free (PRF) IMEM was used to strip cells of endogenous estrogens. Calf serum was treated with dextrancoated activated charcoal McLeskey et al., 1998 ) to obtain CCS.
Plasmids and expression constructs
The PTB domains of SNT-1 (Genbank accession number AF036717) and SNT-2 (Genbank accession number AF036718) were obtained by RT-PCR using total RNA isolated from MCF-7 cells by the phenol-chloroform procedure (Xie and Rothblum 1991) . The PCR fragment of the SNT-1 PTB domain was amplified using the following primers: sense primer 5 0 -AAGCTT GCCATG GTAGC TGTTGTA GC-3 0 , antisense primer 5 0 -CTCGAG TCCTGG AGTTGT AGGTGT-3 0 . The SNT-1 PTB domain was cloned into pEF6/ MycHisA (Invitrogen) upstream of an in-frame c-myc epitope. Tagged SNT-1 PTB was then cloned into the vector pTREins previously constructed in our laboratory for Dox-inducible expression (Qu et al., 2004) . The following primers were used to amplify SNT-2 PTB domain using total RNA isolated from human placenta and from ML20 cells: sense primer 5 0 -GGA TCC GACACC ATGGGG AGCTGC TGCAGC-3 0 , antisense primer 5 0 -GAATTC CTACAG AGGCAGGTCGGTG CT-3 0 . RT-PCR was performed using the Access RT-PCR system from Promega (Madison, WI, USA).
Doxycycline-inducible expression of SNT-1 PTB To avoid selection for cells that may utilize compensatory mechanisms when SNT-1 PTB is overexpressed, we used a regulatable system that allowed us to achieve high levels of SNT-1 PTB expression only in the presence of Dox with no detectable basal expression. We employed a system with a synthetic reverse tet transactivator, rtTA2S-M2, containing three copies of a minimal VP-16 domain that is devoid of the toxicity of the strong VP-16 full-length transactivator (Urlinger et al., 2000) . In addition, the 'tet-repressor' component of the fusion protein is engineered with substitutions that enable its activation by very low concentrations of Dox (Urlinger et al., 2000) . We constructed a bicistronic expression vector that contained an internal ribosome entry site (IRES)-linked blasticidin-resistance gene for this modified transactivator (Qu et al., 2004) . Inclusion of IRES and a selectable drug-resistance gene increased the frequency with which clones expressing functional transctivator were obtained. A stable ML20 line transfected with CMV-driven rtTA2S-M2, called C9, was first isolated (Qu et al., 2004) . We then constructed a tet-inducible SNT-1 PTB vector. In this vector, the TRE-SNT-1 PTB module was flanked by two double copies of a 250 bp 'insulator' from the chicken b-globin 5 0 hypersensitive site resulting in the expression construct pTREins/PTB. This insulator has been shown to protect transgenes from being silenced and also to protect these genes from nearby enhancers (Bell et al., 2001) . Flanking the TRE-reporter gene with double copies of this core element virtually eliminated expression in the uninduced state (Qu et al., 2004) . The C9 line was retransfected with the pTREins/PTB vector.
Stable transfection strategies
To obtain clonal and polyclonal populations of ML20 cells expressing the SNT-1 PTB domain in Dox-inducible manner, C9 cells were seeded in 100-mm tissue culture dishes in 5% FBS IMEM. Cells were co-transfected the next day in serum-free IMEM medium with pTREins/PTB and the pZeoSV vector that confers resistance to Zeocin s using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA). Control cultures were cotransfected with the vector pTREins and pZeoSV. Transfected cells were selected in the presence of 100 mg/ml of Zeocin s . Separate colonies and total pools were further expanded in the presence of Zeocin s . Clones expressing high levels of myctagged SNT-1 PTB in a Dox-inducible manner were screened by immunofluorescence using anti-myc antibodies.
Immunofluorescence microscopy Cells were seeded to about 60% confluency on chamber slides. The expression of SNT-1 PTB was induced by incubation with Dox (200 ng/ml) for 48 h. On the day of the experiment, the cells were washed with PBS and fixed with 4% paraformaldehyde (in PBS) for 10 min. After two washes with PBS, cells were permeabilized in 0.3% Triton X-100 (in PBS) for 5 min and subsequently washed with PBS. Cells were blocked with 5% normal goat serum (in PBS) for 1 h and incubated with the anti-c-myc antibody for 1 h. After three washes with PBS, incubation with secondary antibody was carried out for 1 h. Slides were washed three times with PBS, mounted with 50% glycerol and examined using a Leica DMLB microscope equipped with a Spot RT Color camera (Diagnostic Instruments, Inc., Sterling Heights, MI, USA). All procedures were performed at room temperature.
Growth factor stimulation ML20 cells were stripped of estrogen with three changes of 5% CCS-PRF-IMEM over 8 h and incubated overnight in serumfree CCS-phenol red free (PRF)-IMEM. Clonal and polyclonal lines expressing Dox-inducible SNT-1 PTB domain were induced with 200 ng/ml of Dox for 24-48 h. Dox remained present in the media during the stripping procedure. Cells were stimulated with 20 ng/ml of FGF-1 in the presence of 50 mg/ml of heparin or with 25 ng/ml of HRG-b1 for 5-30 min prior to lysis. Subsequently, cells were washed once in ice-cold PBS and lysed using 10 Â Cell Lysis Buffer (Cell Signalling Technology, Beverly, MA, USA) supplemented with 1 mM PMSF. Protein concentrations were determined using the BCA Protein Assay kit (Pierce, Rockford, IL, USA). Lysates were then analysed by Western immunoblotting as described below or used for immunoprecipitation.
p13
Suc1 agarose precipitaton p13 Suc1 agarose (Upstate Biotechnology, Charlottesville, VA, USA) was used to precipitate endogenous SNT-1 protein from cellular lysates (Rabin et al., 1993) . In total, 20-30 ml of a 50% gel slurry was incubated with 1-2 mg of protein from total cellular lysates for 18 h at 41C. The precipitates were washed three times in lysis buffer, boiled for 5 min in 2 Â Laemmli sample buffer before SDS-polyacrylamide electrophoresis in 7% gels, then subjected to immunoblotting with different antibodies.
Active Ras pulldown assays Active Ras pulldown assays were performed using the Ras Activation Assay Kit (Upstate Biotechnology, Charlottesville, VA, USA). ML20 cells expressing the Dox-inducible SNT-1 PTB domain were stripped of estrogen and induced with 200 ng/ml of Dox, as described above and stimulated with FGF-1 and HRG-b1 for 5 min. Cellular lysate proteins (500 mg) were incubated with 10 mg of Raf-1 Ras Binding Domain (RBD) bound to agarose at 41C for 30 min and centrifuged at 14 000 g for 5 s. Pellets were washed three times with lysis buffer, boiled 5 min in 2 Â Laemmli sample buffer before SDS-polyacrylamide electrophoresis in 12% gels followed by immunoblotting with anti-Ras antibodies.
Western blotting
Western blotting was performed on lysates prepared from ML20 cells treated with the appropriate conditions. Cellular lysates were run on Criterion s pre-cast SDS-polyaerylamide gel electrophoresis (PAGE) gels (Bio-Rad, Hercules, CA, USA). Proteins were transferred onto Trans-Blot s nitrocellulose membrane (Bio-Rad) by electroblotting. The blots were 
Colony forming tests
Cells were plated at 1200 per 35 mm dish in 5% PRF-FBS-IMEM and were allowed to attach overnight. The expression of SNT-1 PTB was induced by Dox (100 ng/ml) in 5% PRF-FBS-IMEM containing 50 mg/ml of heparin and the following additions: ICI 182 780 at 10 À7 M, FGF-1 at 20 ng/ml, HRG-b1 at 25 ng/ml, 17b-estradiol at 10 À7 M. Media were changed every 48 h for a period of 3 weeks. Colonies were fixed with formalin, stained with 0.05% crystal violet in saline and counted. P-values were determined by the paired t-test.
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